Patent: 8,329,419
✉ Email this page to a colleague
Summary for Patent: 8,329,419
| Title: | GLP-1 receptor agonist bioassays |
| Abstract: | Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays. |
| Inventor(s): | Nicolaou; Michalis (San Diego, CA), Bancroft; Frederick Charles (Carlsbad, CA), Herich; John Patrick (Cardiff, CA), Gupta; Swati (San Diego, CA), Lwin; Aung Naing (Carlsbad, CA) |
| Assignee: | Amylin Pharmaceuticals, LLC (San Diego, CA) Astrazeneca Pharmaceuticals LP (Wilmington, DE) |
| Application Number: | 12/990,693 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,329,419
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | 04/15/2014 | ⤷ Try a Trial | 2028-05-23 |
| Sanofi-aventis U.s. Llc | ADLYXIN | lixisenatide | Injection | 208471 | 07/27/2016 | ⤷ Try a Trial | 2028-05-23 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
